40
Participants
Start Date
February 28, 2022
Primary Completion Date
February 28, 2023
Study Completion Date
July 31, 2023
Apomorphine Injectable Solution
"Patients will receive the treatment while they are in an OFF period, without the effect of any antiparkinsonian medication. For this study, the initial dose of apomorphine or placebo will be 2 mg. We selected an initial standardized dose based on the pharmacological characteristics of apomorphine. Assessments will be completed 30 and 60 minutes after the initial dose. At 60 minutes from the first dose, a 3 mg dose will be administered, and again, assessments will be completed after 30 and 60 minutes. The total given dosage will be 5 mg. Blood pressure and pulse will be checked every 20 minutes after injections.~Other Names:~Movapo"
Placebo
"0.9% saline placebo injection~Other Names:~• Saline"
RECRUITING
Movement Disorder Program, Foothills Medical Center, Alberta Health Services, Calgary
Collaborators (1)
Paladin Labs Inc.
OTHER
University of Calgary
OTHER